1. Home
  2. KNDI vs TLSA Comparison

KNDI vs TLSA Comparison

Compare KNDI & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KNDI

Kandi Technologies Group Inc

HOLD

Current Price

$0.83

Market Cap

67.8M

ML Signal

HOLD

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$0.00

Market Cap

155.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KNDI
TLSA
Founded
2002
2013
Country
China
United Kingdom
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.8M
155.2M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
KNDI
TLSA
Price
$0.83
N/A
Analyst Decision
Analyst Count
0
Target Price
N/A
N/A
AVG Volume (30 Days)
171.4K
N/A
Earning Date
04-27-2026
04-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.78
N/A
52 Week High
$1.77
N/A

Technical Indicators

Market Signals
Indicator
KNDI
TLSA
Relative Strength Index (RSI) 37.59 44.96
Support Level $0.81 N/A
Resistance Level $1.19 $1.62
Average True Range (ATR) 0.07 0.11
MACD -0.01 -0.00
Stochastic Oscillator 15.50 29.82

Price Performance

Historical Comparison
KNDI
TLSA

About KNDI Kandi Technologies Group Inc

Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.

Share on Social Networks: